{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where agency_id = \"FDA\" and docket_id = \"FDA-2009-N-0582\" sorted by posted_date descending", "rows": [["FDA-2009-N-0582-0132", "FDA", "FDA-2009-N-0582", "TAB A-2016-994-Direct to Consumer-Final  Rule-Original", "Supporting & Related Material", "Background Material", "2024-01-05T05:00:00Z", 2024, 1, null, null, "2024-01-05T13:40:49Z", null, 0, 0, "0900006486375b66"], ["FDA-2009-N-0582-0131", "FDA", "FDA-2009-N-0582", "Direct to Consumer Memorandum", "Supporting & Related Material", "Memorandum", "2024-01-05T05:00:00Z", 2024, 1, null, null, "2024-01-05T13:40:49Z", null, 0, 0, "0900006486375b65"], ["FDA-2009-N-0582-0135", "FDA", "FDA-2009-N-0582", "TAB B-2016-994-Direct to Consumer-FRIA-TRACK CHANGE FROM ORIGINAL TO FINAL", "Supporting & Related Material", "Background Material", "2024-01-05T05:00:00Z", 2024, 1, null, null, "2024-01-05T13:40:51Z", null, 0, 0, "0900006486375b69"], ["FDA-2009-N-0582-0134", "FDA", "FDA-2009-N-0582", "TAB B-2016-994-Direct to Consumer-Final Rule-TRACK CHANGE FROM ORIGINAL TO FINAL", "Supporting & Related Material", "Background Material", "2024-01-05T05:00:00Z", 2024, 1, null, null, "2024-01-05T13:40:50Z", null, 0, 0, "0900006486375b68"], ["FDA-2009-N-0582-0136", "FDA", "FDA-2009-N-0582", "TAB C-2016-994-Direct to Consumer FRIA-Final", "Supporting & Related Material", "Background Material", "2024-01-05T05:00:00Z", 2024, 1, null, null, "2024-01-05T13:40:52Z", null, 0, 0, "0900006486375b6a"], ["FDA-2009-N-0582-0133", "FDA", "FDA-2009-N-0582", "TAB-A-2016-994-Direct to Consumer-FRIA-Orginal", "Supporting & Related Material", "Background Material", "2024-01-05T05:00:00Z", 2024, 1, null, null, "2024-01-05T13:40:50Z", null, 0, 0, "0900006486375b67"], ["FDA-2009-N-0582-0137", "FDA", "FDA-2009-N-0582", "TAB C-2016-994-Direct to Consumer-Final Rule-Final", "Supporting & Related Material", "Background Material", "2024-01-05T05:00:00Z", 2024, 1, null, null, "2024-01-05T13:40:52Z", null, 0, 0, "0900006486375b6b"], ["FDA-2009-N-0582-0130", "FDA", "FDA-2009-N-0582", "Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear,\nConspicuous, and Neutral Manner in Advertisements in Television and Radio Format Final Rule: Questions and Answers; Guidance for Industry; Small Entity Compliance Guide; Availability", "Rule", "Final Rule with Request for Comments", "2023-12-27T05:00:00Z", 2023, 12, "2023-12-27T05:00:00Z", null, "2023-12-27T14:34:36Z", "2023-28530", 0, 0, "090000648635c371"], ["FDA-2009-N-0582-0129", "FDA", "FDA-2009-N-0582", "Agency Information Collection Activities; Proposals, Submissions, and Approvals", "Notice", "Notice of Approval", "2023-12-22T05:00:00Z", 2023, 12, null, null, "2024-01-08T13:23:07Z", "2023-28290", 0, 0, "0900006486351614"], ["FDA-2009-N-0582-0061", "FDA", "FDA-2009-N-0582", "Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Rule", "Direct Final Rule", "2023-11-21T05:00:00Z", 2023, 11, "2023-11-21T05:00:00Z", null, "2024-01-05T14:03:16Z", "2023-25428", 0, 0, "090000648629f6eb"], ["FDA-2009-N-0582-0070", "FDA", "FDA-2009-N-0582", "08 Reference 8 How DTC Spending Shifted in 2020_Medical Marketing and Media_2021 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:16:07Z", null, 0, 0, "090000648629f8c1"], ["FDA-2009-N-0582-0090", "FDA", "FDA-2009-N-0582", "28 Reference 28 Capacity Limits in Selective Attention Behavioral Evidence and Implications for Neural Activity_Lavie_2001 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:31:22Z", null, 0, 0, "09000064862a052d"], ["FDA-2009-N-0582-0092", "FDA", "FDA-2009-N-0582", "30 Reference 30 Temporal Methods for Studying Attention How Did We Get Here and Where Are We Going_Shapiro_2001 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:32:32Z", null, 0, 0, "09000064862a052f"], ["FDA-2009-N-0582-0115", "FDA", "FDA-2009-N-0582", "53 Reference 53 The Implications of the FTC's Clear and Conspicuous Standards for the Communication of Credit Card Information to Young Consumers_Thomas_2011 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:42:50Z", null, 0, 0, "09000064862a0679"], ["FDA-2009-N-0582-0105", "FDA", "FDA-2009-N-0582", "43 Reference 43 Aging and Direct-to-Consumer Prescription Drug Television Ads The Effects of Individual Differences and Risk Presentation_O'Donoghue_2019 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:40:54Z", null, 0, 0, "09000064862a058f"], ["FDA-2009-N-0582-0112", "FDA", "FDA-2009-N-0582", "50 Reference 50 H. Rept. No.102-839_1992 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:42:11Z", null, 0, 0, "09000064862a05d8"], ["FDA-2009-N-0582-0103", "FDA", "FDA-2009-N-0582", "41 Reference 41 Age Affective Experience and Television Use_Depp_2010", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:40:41Z", null, 0, 0, "09000064862a05da"], ["FDA-2009-N-0582-0118", "FDA", "FDA-2009-N-0582", "56 Reference 56 Effect of Presentation Modality in Direct-to-Consumer (DTC) Prescription Drug Television Advertisements_Wogalter_2014 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:43:24Z", null, 0, 0, "09000064862a06c3"], ["FDA-2009-N-0582-0062", "FDA", "FDA-2009-N-0582", "00 References List CCN Final Rule 10-24-23", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:11:41Z", null, 0, 0, "090000648629f897"], ["FDA-2009-N-0582-0064", "FDA", "FDA-2009-N-0582", "02 Reference 2 Direct-to-Consumer Advertising of Prescription Drugs and the Patient Prescriber Encounter A Systematic Review_DeFrank_2020 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:12:03Z", null, 0, 0, "090000648629f899"], ["FDA-2009-N-0582-0076", "FDA", "FDA-2009-N-0582", "14 Reference 14 Factors Influencing Consumers' Attitudinal and Behavioral Responses to Direct-to-Consumer and Over-the-Counter Drug Advertising_Lee_2015 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:17:49Z", null, 0, 0, "090000648629f8c7"], ["FDA-2009-N-0582-0086", "FDA", "FDA-2009-N-0582", "24 Reference 24 An Integrated Career Coaching and Time-Banking System Promoting FlexibilityWellness  and Success A Pilot Program at Stanford University School of Medicine_Fassiotto_2018 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:20:34Z", null, 0, 0, "09000064862a0528"], ["FDA-2009-N-0582-0088", "FDA", "FDA-2009-N-0582", "26 Reference 26 Draft Guidance for Industry Presenting Risk Information in Prescription Drug and Medical Device Promotion_FDA_2009 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:20:50Z", null, 0, 0, "09000064862a052a"], ["FDA-2009-N-0582-0097", "FDA", "FDA-2009-N-0582", "35 Reference 35 Music is as Distracting as Noise The Differential Distraction of Background Music and Noise on the Cognitive Test Performance of Introverts and Extraverts_Furnham_2002 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:39:39Z", null, 0, 0, "09000064862a058b"], ["FDA-2009-N-0582-0100", "FDA", "FDA-2009-N-0582", "38 Reference 38 Sources of Miscomprehension in Television Advertising_Hoyer_1984 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:39:57Z", null, 0, 0, "09000064862a058e"], ["FDA-2009-N-0582-0108", "FDA", "FDA-2009-N-0582", "46 Reference 46 Provision of Effective Information_Baker_2006", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:41:44Z", null, 0, 0, "09000064862a05dc"], ["FDA-2009-N-0582-0091", "FDA", "FDA-2009-N-0582", "29 Reference 29 The Magical Number Seven Plus or Minus Two Some Limits on Our Capacity for Processing Information_Miller_1956 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:32:20Z", null, 0, 0, "09000064862a052e"], ["FDA-2009-N-0582-0099", "FDA", "FDA-2009-N-0582", "37 Reference 37 Distraction and Attitude Change A Resolution_Regan_1973 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:39:51Z", null, 0, 0, "09000064862a058d"], ["FDA-2009-N-0582-0110", "FDA", "FDA-2009-N-0582", "48 Reference 48 Quantifying Perceived Differences in Type Styles An Exploratory Study_Tantillo_1995 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:41:58Z", null, 0, 0, "09000064862a0591"], ["FDA-2009-N-0582-0079", "FDA", "FDA-2009-N-0582", "17 Reference 17 Consumers Reports on the Health Effects of Direct-to-Consumer Drug AdvertisingWeissman2003 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:18:38Z", null, 0, 0, "090000648629f8f6"], ["FDA-2009-N-0582-0083", "FDA", "FDA-2009-N-0582", "21 Reference 21 Time Allocation in Primary Care Office Visits_Tai-Seale_2007 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:19:39Z", null, 0, 0, "090000648629f8fa"], ["FDA-2009-N-0582-0116", "FDA", "FDA-2009-N-0582", "54 Reference 54 An Empirical Examination of the FDAAA-Mandated Toll-Free Statement for Consumer Reporting of Side Effects in Direct-to-Consumer Television Advertisements_Aikin_2016 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:43:00Z", null, 0, 0, "09000064862a06ad"], ["FDA-2009-N-0582-0109", "FDA", "FDA-2009-N-0582", "47 Reference 47 Text Legibility and the Letter Superiority Effect_Sheedy_2005", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:41:50Z", null, 0, 0, "09000064862a05de"], ["FDA-2009-N-0582-0125", "FDA", "FDA-2009-N-0582", "63 Reference 63 Defining Audio-Video Redundancy From a Limited-Capacity Information Processing Perspective_Lang_1995 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:44:22Z", null, 0, 0, "09000064862a067a"], ["FDA-2009-N-0582-0120", "FDA", "FDA-2009-N-0582", "58 Reference 58 The Empirical Case for Dual Coding_Paivio_1983 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:43:43Z", null, 0, 0, "09000064862a067b"], ["FDA-2009-N-0582-0074", "FDA", "FDA-2009-N-0582", "12 Reference 12 Kaiser Health Tracking Poll October 2015_DiJulio_2015 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:17:32Z", null, 0, 0, "090000648629f8c5"], ["FDA-2009-N-0582-0080", "FDA", "FDA-2009-N-0582", "18 Reference 18 Fair Balance in Direct-to-Consumer Antidepressant Print and Television Advertising_Avery_2012 \nRE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:18:51Z", null, 0, 0, "090000648629f8f7"], ["FDA-2009-N-0582-0089", "FDA", "FDA-2009-N-0582", "27 Reference 27 Experimental Evaluation of the Impact of Distraction on Consumer Understanding of Risk and Benefit Information Technical Research Report_FDA_2011RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:21:06Z", null, 0, 0, "09000064862a052b"], ["FDA-2009-N-0582-0075", "FDA", "FDA-2009-N-0582", "13 Reference 13 2017 Direct-to-Consumer Advertising Survey Results_Princeton Survey Research Associates for PhRMA_2017 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:17:38Z", null, 0, 0, "090000648629f8c6"], ["FDA-2009-N-0582-0065", "FDA", "FDA-2009-N-0582", "03 Reference 3 Promotion of Prescription Drugs to Consumers and Providers 20012010_Kornfield_2013 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:12:12Z", null, 0, 0, "09000064862a084c"], ["FDA-2009-N-0582-0093", "FDA", "FDA-2009-N-0582", "31 Reference 31 Factors That Guide or Disrupt Attentive Visual Processing_Hillstrom_2006 \nRE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:32:38Z", null, 0, 0, "09000064862a0530"], ["FDA-2009-N-0582-0101", "FDA", "FDA-2009-N-0582", "39 Reference 39 The Effect of Background Music and Background Noise on the Task Performance of Introverts and Extraverts_Cassidy_2007 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:40:21Z", null, 0, 0, "09000064862a0590"], ["FDA-2009-N-0582-0106", "FDA", "FDA-2009-N-0582", "44 Reference 44 Quantifying and Predicting the Effects of Basic Text Display Variables on the Perceived Urgency of Warning Labels_Adams_1995 \n\nRE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:41:18Z", null, 0, 0, "09000064862a05d5"], ["FDA-2009-N-0582-0113", "FDA", "FDA-2009-N-0582", "51 Reference 51 The Self-Confidence Advertising Response Relationship A Function of Situational Disctraction_Bither_1973", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:42:23Z", null, 0, 0, "09000064862a0614"], ["FDA-2009-N-0582-0127", "FDA", "FDA-2009-N-0582", "65 Reference 65 Commission Enforcement Policy Statement in Regard to Clear and Conspicuous Disclosure in Television Advertising_FTC_1970 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:44:39Z", null, 0, 0, "09000064862a067f"], ["FDA-2009-N-0582-0096", "FDA", "FDA-2009-N-0582", "34 Reference 34 Comprehension of Info-Aid Supers in Television Advertising for Social Ideas Implications for Public Policy_Manrai_1994 \nRE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:32:58Z", null, 0, 0, "09000064862a058a"], ["FDA-2009-N-0582-0123", "FDA", "FDA-2009-N-0582", "61 Reference 61 What Effect Do Mixed Sensory Mode Instructional Formats Have on Both Novice and Experienced Learners of Chinese Characters_Chung_2008 RE:Direct-to-Consumer Prescription Drug  Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:44:03Z", null, 0, 0, "09000064862a06c5"], ["FDA-2009-N-0582-0082", "FDA", "FDA-2009-N-0582", "20 Reference 20 Patients Willing to Wait Arrival Time Wait Time and Patient Satisfaction in an Ambulatory Urology Clinic_Donahue_2017 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:19:10Z", null, 0, 0, "090000648629f8f9"], ["FDA-2009-N-0582-0084", "FDA", "FDA-2009-N-0582", "22 Reference 22 A Time Motion Study of Primary Care Physicians' Work in the Electronic Health Record Era_Young_2018 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:20:14Z", null, 0, 0, "090000648629f8fb"], ["FDA-2009-N-0582-0063", "FDA", "FDA-2009-N-0582", "01 Reference 1 Guidance for Industry Consumer-Directed Broadcast Advertisements_FDA_1999 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:11:52Z", null, 0, 0, "090000648629f898"], ["FDA-2009-N-0582-0066", "FDA", "FDA-2009-N-0582", "04 Reference 4 Trends in Exposure to Televised Prescription Drug Advertising 20032011Kornfield2015 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:15:07Z", null, 0, 0, "090000648629f89a"], ["FDA-2009-N-0582-0121", "FDA", "FDA-2009-N-0582", "59 Reference 59 The Effects of Audio-Visual and Visual-Only Cues on Consumers Responses to Co-Branded Advertising_Wang_2010 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:43:49Z", null, 0, 0, "09000064862a06ae"], ["FDA-2009-N-0582-0072", "FDA", "FDA-2009-N-0582", "10 Reference 10 An Updated Analysis of DTC TV Advertisements for Prescription Drugs_Applequist_2018 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:16:58Z", null, 0, 0, "090000648629f8c3"], ["FDA-2009-N-0582-0077", "FDA", "FDA-2009-N-0582", "15 Reference 15 Patient and Physician Attitudes and Behaviors Associated With DTC Promotion of Prescription Drugs Summary of FDA Survey Research Results_Aikin_2004 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:17:59Z", null, 0, 0, "090000648629f8f4"], ["FDA-2009-N-0582-0111", "FDA", "FDA-2009-N-0582", "49 Reference 49 Effects of Label Format on Knowledge Acquisition and Perceived Readability by Younger and Older Adults_Wogalter_2003 \nRE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:42:05Z", null, 0, 0, "09000064862a05d6"], ["FDA-2009-N-0582-0128", "FDA", "FDA-2009-N-0582", "66 Reference 66 Economic Analysis of Impacts Direct-to-Consumer Prescription Drug Advertisements_FDA_2023 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:44:49Z", null, 0, 0, "09000064862a06b2"], ["FDA-2009-N-0582-0104", "FDA", "FDA-2009-N-0582", "42 Reference 42 Prescription Drug Use Continues to Increase U.S. Prescription Drug Data for 20072008 NCHS Data Brief_Gu_2010", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:40:47Z", null, 0, 0, "09000064862a05dd"], ["FDA-2009-N-0582-0119", "FDA", "FDA-2009-N-0582", "57 Reference 57 Cognitive Psychology In and Out of the Laboratory_Galotti_2004 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:43:38Z", null, 0, 0, "09000064862a0676"], ["FDA-2009-N-0582-0117", "FDA", "FDA-2009-N-0582", "55 Reference 55 Attention to and Distraction from Risk Information in Prescription Drug Advertising An Eye Tracking Study_Sullivan_2017", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:43:07Z", null, 0, 0, "09000064862a06c0"], ["FDA-2009-N-0582-0094", "FDA", "FDA-2009-N-0582", "32 Reference 32 Distraction Can Enhance or Reduce Yielding to Propaganda Thought Disruption Versus Effort Justification_Petty_1976 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:32:43Z", null, 0, 0, "09000064862a0588"], ["FDA-2009-N-0582-0095", "FDA", "FDA-2009-N-0582", "33 Reference 33 Modifying the Impact of Persuasive Communications with External Distraction_Zimbardo_1970 \nRE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:32:48Z", null, 0, 0, "09000064862a0589"], ["FDA-2009-N-0582-0102", "FDA", "FDA-2009-N-0582", "40 Reference 40 Clear and Conspicuous Disclosure_CCH Trade Regulation Reporter_1970 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:40:31Z", null, 0, 0, "09000064862a05d7"], ["FDA-2009-N-0582-0107", "FDA", "FDA-2009-N-0582", "45 Reference 45 Serifs and Font Legibility_Arditi_2005", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:41:35Z", null, 0, 0, "09000064862a05d9"], ["FDA-2009-N-0582-0126", "FDA", "FDA-2009-N-0582", "64 Reference 64 Recall of Television Versus Print News Retesting the Semantic Overlap Hypothesis_Walma_2004 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:44:32Z", null, 0, 0, "09000064862a067c"], ["FDA-2009-N-0582-0068", "FDA", "FDA-2009-N-0582", "06 Reference 6 Trends in Urological Direct-to-Consumer Advertising during Prime-Time Television News Programs_Koo_2017 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:15:23Z", null, 0, 0, "090000648629f8bf"], ["FDA-2009-N-0582-0073", "FDA", "FDA-2009-N-0582", "11 Reference 11 PhRMA Guiding Principles Direct to Consumer Advertisements About Prescription Medicines_PhRMA_2008 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:17:18Z", null, 0, 0, "090000648629f8c4"], ["FDA-2009-N-0582-0069", "FDA", "FDA-2009-N-0582", "07 Reference 7 US Congressional Research Service_Direct-to-Consumer Advertising of Prescription Drugs Report_2009 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:15:34Z", null, 0, 0, "090000648629f8c0"], ["FDA-2009-N-0582-0078", "FDA", "FDA-2009-N-0582", "16 Reference 16 Scientific Literature on Direct-to-Consumer Advertising of Prescription Pharmaceuticals 20042008 Literature ReviewEastern Research Group2009 \nRE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:18:08Z", null, 0, 0, "090000648629f8f5"], ["FDA-2009-N-0582-0071", "FDA", "FDA-2009-N-0582", "09 Reference 9 The Top 10 Ad Spenders in Big Pharma for 2020_Fierce Pharma_Bulik 2021 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:16:16Z", null, 0, 0, "090000648629f8c2"], ["FDA-2009-N-0582-0081", "FDA", "FDA-2009-N-0582", "19 Reference 19 Communicating Uncertainties About Prescription Drugs to the Public A National Randomized Trial_Schwartz_2011 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:18:59Z", null, 0, 0, "090000648629f8f8"], ["FDA-2009-N-0582-0085", "FDA", "FDA-2009-N-0582", "23 Reference 23 Direct-to-Consumer Advertising Physicians' Views of Its Effects on Quality of Care and the Doctor-Patient Relationship_Murray_2003 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:20:26Z", null, 0, 0, "09000064862a0527"], ["FDA-2009-N-0582-0087", "FDA", "FDA-2009-N-0582", "25 Reference 25 Allocation of Physician Time in Ambulatory Practice A Time and Motion Study in 4 Specialties_Sinsky_2016 \nRE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:20:43Z", null, 0, 0, "09000064862a0529"], ["FDA-2009-N-0582-0124", "FDA", "FDA-2009-N-0582", "62 Reference 62 Using Both an Auditory and a Visual Short-Term Store to Increase Digit Span_Frick_1984 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:44:17Z", null, 0, 0, "09000064862a061d"], ["FDA-2009-N-0582-0114", "FDA", "FDA-2009-N-0582", "52 Reference 52 Music to Your Brain Background Music Changes Are Processed First Reducing Ad Message Recall_Fraser_2013 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:42:40Z", null, 0, 0, "09000064862a061b"], ["FDA-2009-N-0582-0098", "FDA", "FDA-2009-N-0582", "36 Reference 36 Processing Deficits and the Mediation of Positive Affect in Persuasion_Mackie_1989 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:39:46Z", null, 0, 0, "09000064862a058c"], ["FDA-2009-N-0582-0122", "FDA", "FDA-2009-N-0582", "60 Reference 60 Improving Comprehension of Jury Instructions with Audio-Visual Presentation_Brewer_2004 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:43:59Z", null, 0, 0, "09000064862a06c2"], ["FDA-2009-N-0582-0067", "FDA", "FDA-2009-N-0582", "05 Reference 5 Do Prescription Drug Ads Tell Consumers Enough About Benefits and Side Effects Results From the Health Information National Trends Survey Fourth_Sullivan_2015 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the\nMajor Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format", "Supporting & Related Material", "Background Material", "2023-11-21T05:00:00Z", 2023, 11, null, null, "2023-11-21T22:15:15Z", null, 0, 0, "090000648629f89b"], ["FDA-2009-N-0582-0055", "FDA", "FDA-2009-N-0582", "Direct-to-Consumer Prescription Drug Advertisements; Presentation of the Major Statement in Television and Radio Advertisements in a Clear, Conspicuous, and Neutral Manner; Reopening of the Comment Period", "Proposed Rule", "Notice of Proposed Rulemaking (NPRM)", "2012-03-23T04:00:00Z", 2012, 3, "2012-03-23T04:00:00Z", "2012-04-10T03:59:59Z", "2023-10-25T16:01:08Z", "2012-06948", 0, 0, "0900006480fdf3d2"], ["FDA-2009-N-0582-0040", "FDA", "FDA-2009-N-0582", "Direct-to-Consumer Prescription Drug Advertisements; Presentation of the Major Statement in Television and Radio Advertisements in a Clear, Conspicuous, and Neutral Manner; Notice of Availability of Study Data", "Proposed Rule", "Notice of Proposed Rulemaking (NPRM)", "2012-01-27T05:00:00Z", 2012, 1, "2012-01-27T05:00:00Z", "2012-02-28T04:59:59Z", "2023-10-25T16:02:27Z", "2012-01672", 0, 0, "0900006480fa7047"], ["FDA-2009-N-0582-0017", "FDA", "FDA-2009-N-0582", "OMB Changes, Executive Order 12866 (E.O.)[Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in Television and Radio Advertisements in a Clear, Conspicuous, and Neutral Manner ] - Reference", "Other", "REF-Reference Material (internal attachments)", "2010-04-27T04:00:00Z", 2010, 4, "2010-04-27T04:00:00Z", null, "2013-08-11T01:34:04Z", null, 0, 0, "0900006480ae15c4"], ["FDA-2009-N-0582-0007", "FDA", "FDA-2009-N-0582", "Reference 12 - \"IMS Health, Total U.S. Promotional Spend By Type, 2008\" - Background", "Supporting & Related Material", "BKG-Background Material", "2010-03-29T04:00:00Z", 2010, 3, null, null, "2010-03-29T15:20:19Z", null, 0, 0, "0900006480ac9fd4"], ["FDA-2009-N-0582-0008", "FDA", "FDA-2009-N-0582", "Reference 13 - \"IMS Health, Integrated Promotional Services\u2122, Year 2008, Data Extracted on September 2009\" - Background", "Supporting & Related Material", "BKG-Background Material", "2010-03-29T04:00:00Z", 2010, 3, null, null, "2010-03-29T15:20:40Z", null, 0, 0, "0900006480ac9fd9"], ["FDA-2009-N-0582-0009", "FDA", "FDA-2009-N-0582", "Reference 15 - \"Office of Management and Budget, Circular A-4, Setember 17, 2003\" - Background", "Supporting & Related Material", "BKG-Background Material", "2010-03-29T04:00:00Z", 2010, 3, null, null, "2010-03-29T15:21:01Z", null, 0, 0, "0900006480ac9ffb"], ["FDA-2009-N-0582-0013", "FDA", "FDA-2009-N-0582", "Reference 19 - \"Scientific Literature on Direct to Consumer Advertising of Precription Pharmaceuticals, 2004-2008; Eastern Research Group, Inc., Literature Review\" - Background", "Supporting & Related Material", "BKG-Background Material", "2010-03-29T04:00:00Z", 2010, 3, null, null, "2010-03-29T15:22:43Z", null, 0, 0, "0900006480aca060"], ["FDA-2009-N-0582-0003", "FDA", "FDA-2009-N-0582", "Reference 1 - \"FDA Guidance for Industry, \"Consumer-Directed Broadcast Advertisements,\" - Background", "Supporting & Related Material", "BKG-Background Material", "2010-03-29T04:00:00Z", 2010, 3, null, null, "2010-03-29T15:18:52Z", null, 0, 0, "0900006480ac9f70"], ["FDA-2009-N-0582-0002", "FDA", "FDA-2009-N-0582", "DDMAC References -  [Note for MONDAY 3/29/2010 - POST THIS DOCUMENT FIRST BUT AFTER THE FR DOCUMENT AND Please Insert the Title of the FR Notice Here]", "Supporting & Related Material", "BKG-Background Material", "2010-03-29T04:00:00Z", 2010, 3, null, null, "2010-03-29T15:18:23Z", null, 0, 0, "0900006480aca149"], ["FDA-2009-N-0582-0001", "FDA", "FDA-2009-N-0582", "Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in Television and Radio Advertisements in a Clear, Conspicuous, and Neutral Manner", "Proposed Rule", "NPR-Notice of Proposed Rule-Making", "2010-03-29T04:00:00Z", 2010, 3, "2010-03-29T04:00:00Z", "2010-06-29T03:59:59Z", "2012-11-30T03:02:04Z", "2010-06996", 0, 0, "0900006480aca825"], ["FDA-2009-N-0582-0010", "FDA", "FDA-2009-N-0582", "Reference 16 - \"Prescription Drugs: FDA Oversight of Direct-to-Consumer Advertising Has Limitations, GAO\" - Background", "Supporting & Related Material", "BKG-Background Material", "2010-03-29T04:00:00Z", 2010, 3, null, null, "2010-03-29T15:21:25Z", null, 0, 0, "0900006480aca03c"], ["FDA-2009-N-0582-0006", "FDA", "FDA-2009-N-0582", "Reference 4 - \"FDA Draft Guidance for Industry, \"Presenting Risk Information in Prescription Drug and Medical Device Promotion,\" - Background", "Supporting & Related Material", "BKG-Background Material", "2010-03-29T04:00:00Z", 2010, 3, null, null, "2010-03-29T15:19:59Z", null, 0, 0, "0900006480ac9f89"], ["FDA-2009-N-0582-0004", "FDA", "FDA-2009-N-0582", "Reference 2 - \"CCH Trade Regulation Reporter, Paragraph 7569.09 \"Clear and Conspicous Disclosure,\" Ocober 21, 1970 - Background", "Supporting & Related Material", "BKG-Background Material", "2010-03-29T04:00:00Z", 2010, 3, null, null, "2010-03-29T15:19:13Z", null, 0, 0, "0900006480ac9f86"], ["FDA-2009-N-0582-0011", "FDA", "FDA-2009-N-0582", "Reference 17 - \"PhRMA Guiding Priniciples; Direct to Consumer Advertisements About Prescription Medicines, Revised December 2008\" - Background", "Supporting & Related Material", "BKG-Background Material", "2010-03-29T04:00:00Z", 2010, 3, null, null, "2010-03-29T15:21:45Z", null, 0, 0, "0900006480aca040"], ["FDA-2009-N-0582-0012", "FDA", "FDA-2009-N-0582", "Reference 18 - \"Patient and Physician Attitudes and Behaviors Associated With DTC Promotion of Prescription Drugs--Summary of FDA Survey Research Results, Final Report, November 19, 2004\" - Background", "Supporting & Related Material", "BKG-Background Material", "2010-03-29T04:00:00Z", 2010, 3, null, null, "2010-03-29T15:22:06Z", null, 0, 0, "0900006480aca044"], ["FDA-2009-N-0582-0005", "FDA", "FDA-2009-N-0582", "Reference 3 - \"See H. Rept. No. 102-839, August 11, 1992\" - Background", "Supporting & Related Material", "BKG-Background Material", "2010-03-29T04:00:00Z", 2010, 3, null, null, "2010-03-29T15:19:36Z", null, 0, 0, "0900006480ac9f87"]], "truncated": false, "filtered_table_rows_count": 93, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"agency_id\" = :p0 and \"docket_id\" = :p1 order by posted_date desc limit 101", "params": {"p0": "FDA", "p1": "FDA-2009-N-0582"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-N-0582", "results": [{"value": "FDA", "label": "FDA", "count": 93, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2009-N-0582", "selected": true}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-N-0582", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 86, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-N-0582&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Proposed Rule", "label": "Proposed Rule", "count": 3, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-N-0582&document_type=Proposed+Rule", "selected": false}, {"value": "Rule", "label": "Rule", "count": 2, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-N-0582&document_type=Rule", "selected": false}, {"value": "Notice", "label": "Notice", "count": 1, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-N-0582&document_type=Notice", "selected": false}, {"value": "Other", "label": "Other", "count": 1, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-N-0582&document_type=Other", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-N-0582", "results": [{"value": 2023, "label": 2023, "count": 70, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-N-0582&posted_year=2023", "selected": false}, {"value": 2010, "label": 2010, "count": 14, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-N-0582&posted_year=2010", "selected": false}, {"value": 2024, "label": 2024, "count": 7, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-N-0582&posted_year=2024", "selected": false}, {"value": 2012, "label": 2012, "count": 2, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-N-0582&posted_year=2012", "selected": false}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-N-0582&_facet=subtype"}, {"name": "posted_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-N-0582&_facet=posted_date"}, {"name": "posted_month", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-N-0582&_facet=posted_month"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-N-0582&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-N-0582&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-N-0582&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-N-0582&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 520.5888550262898, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}